Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma

Background Addition of anti‐GD2 antibody ch14.18 to the treatment of neuroblastoma has improved outcomes. The most common side effect of ch14.18 is neuropathic pain, which may in part be complement‐mediated. Hu14.18K322A is a humanized anti‐GD2 antibody designed to diminish complement activation and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric blood & cancer 2015-02, Vol.62 (2), p.224-228
Hauptverfasser:	Anghelescu, Doralina L., Goldberg, Jacob L., Faughnan, Lane G., Wu, Jianrong, Mao, Shenghua, Furman, Wayne L., Santana, Victor M., Navid, Fariba
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent anti-GD2 antibodies Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Child Child, Preschool Complement Activation - immunology Complement Inactivator Proteins - therapeutic use Complement System Proteins - drug effects Female Gangliosides - antagonists & inhibitors Gangliosides - immunology Hematology Humans Immunotherapy - methods Infant Male Neuralgia - drug therapy neuroblastoma Neuroblastoma - therapy Oncology opioids pain pediatric oncology Pediatrics Retrospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!